Neutropenia in myeloablative therapy

Indication for Lenograstim

Population group: Suitable for both men and women, only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Lenograstim is indicated in adults, adolescents and children aged older than 2 years for the reduction of the duration of neutropenia in patients (with non myeloid malignancy) undergoing myeloablative therapy followed by bone marrow transplantation (BMT) and considered to be at increased risk of prolonged severe neutropenia.

For this indication, competent medicine agencies globally authorize below treatments:

150 μg/m² once daily

Route of admnistration

Subcutaneous

Defined daily dose

150 - 150 ug per m² of body surface area (BSA)

Dosage regimen

From 150 To 150 ug per m² of body surface area (BSA) once every day

Detailed description

Lenograstim should be administered daily at the recommended dose of 19.2 MIU (150 µg) per m² per day as a 30-minute intravenous infusion diluted in isotonic saline solution or as a subcutaneous injection. The first dose should not be administered within 24 hours of the bone marrow infusion. Dosing should continue until the expected nadir has passed and the neutrophil count returns to a stable level compatible with treatment discontinuation, with, if necessary, a maximum of 28 consecutive days of treatment.

It is anticipated that by day 14 following bone marrow transplantation, 50% of patients will achieve neutrophil recovery.

19.2 MIU/m² once daily

Route of admnistration

Subcutaneous

Defined daily dose

19,200,000 - 19,200,000 [iU] per m² of body surface area (BSA)

Dosage regimen

From 19,200,000 To 19,200,000 [iU] per m² of body surface area (BSA) once every day

Detailed description

Lenograstim should be administered daily at the recommended dose of 19.2 MIU (150 µg) per m² per day as a 30-minute intravenous infusion diluted in isotonic saline solution or as a subcutaneous injection. The first dose should not be administered within 24 hours of the bone marrow infusion. Dosing should continue until the expected nadir has passed and the neutrophil count returns to a stable level compatible with treatment discontinuation, with, if necessary, a maximum of 28 consecutive days of treatment.

It is anticipated that by day 14 following bone marrow transplantation, 50% of patients will achieve neutrophil recovery.

Active ingredient

Lenograstim belongs to the cytokine group of biologically active proteins which regulate cell differentiation and cell growth. Lenograstim induces a marked increase in peripheral blood neutrophil counts within 24 hours of administration.

Read more about Lenograstim

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner